REYON PHARMACEUTICAL CO., LTD
Financials
Valuation Metrics
REYON PHARMACEUTICAL CO., LTD's Market Cap is ₩1755B. At end of 2025 it was ₩2004B. Ranked #877 of 2,405 in KR market (top 36%), #471 of 778 on KOSPI (top 61%), #100 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 175.46B KRW | KR#877/2,405 Sec#100/231 |
| Revenue | 143.37B KRW | KR#1,212/2,405 Sec#74/231 |
| Net Income | -34.24B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 444.37B KRW | KR#832/2,405 Sec#51/231 |
| Net Assets | 194.87B KRW | KR#962/2,405 Sec#67/231 |
| Employees | 449 | KR#546/2,405 Sec#43/231 |
| Value | ||
| P/B | 0.90x | KR#1,440/2,405 Sec#89/231 |
| P/S | 1.22x | KR#1,559/2,405 Sec#91/231 |
| FCF Yield | -3.68% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -17.57% | KR#2,062/2,405 Sec#161/231 |
| ROA | -7.71% | KR#2,039/2,405 Sec#151/231 |
| Op. Margin | -20.23% | KR#2,112/2,405 Sec#146/231 |
| Revenue Growth | -4.45% | KR#1,739/2,405 Sec#165/231 |
| Financial Health | ||
| Debt Ratio | 128.03% | KR#1,768/2,405 Sec#197/231 |
| Total Debt | 215.01B KRW | KR#494/2,405 Sec#23/231 |
| FCF | -6.46B KRW | KR#1,564/2,405 Sec#126/231 |
| Cash | 7.02B KRW | KR#1,872/2,405 Sec#166/231 |
| Current Ratio | 0.50x | KR#2,128/2,405 Sec#207/231 |
| Dividend | ||
| Div. Growth | 0.48% | KR#685/2,405 Sec#37/231 |
| Performance | ||
| 1Y Return | -12.51% | KR#935/2,405 Sec#54/231 |
| 1M Return | -6.72% | KR#872/2,405 Sec#83/231 |
| From 52W High | -28.48% | KR#370/2,405 Sec#24/231 |
| 1Y MDD | -25.54% | KR#145/2,405 Sec#10/231 |
| Trading | ||
| Volume | 5,006 shares | KR#2,099/2,405 Sec#213/231 |
| Trading Value | 47.0M KRW | KR#1,754/2,405 Sec#186/231 |
| Foreign Own. | 1.08% | KR#1,995/2,405 Sec#197/231 |
| Per Share | ||
| EPS | -1,842 KRW | KR—/2,405 Sec—/231 |
| BPS | 10,484 KRW | KR#961/2,405 Sec#65/231 |
Company Info
Headquartered in Gangnam-gu, Seoul, E-Yang Pharmaceutical was established in 1964, promoting the domestic production of pharmaceutical raw materials and expanding into new technology business finance in 2017. The company holds various prescription medicines for multiple indications, exclusively supplies original medicines like Optiray, and sells active pharmaceutical ingredients such as Tacrolimus. To become a global bio & chemical pharmaceutical company, it collaborates with bio-ventures on new drug development, with its KGMP-certified Chungju factory driving an R&D business model.